Drug class in one race
HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinal cholesterol transporter (ezetimibe component) drugs for Atherosclerotic Cardiovascular Disease
2 tracked HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinal cholesterol transporter (ezetimibe component) drugs in the Atherosclerotic Cardiovascular Disease race. The class explanation lives on the HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinal cholesterol transporter (ezetimibe component) page; the full indication pipeline across every mechanism is on the Atherosclerotic Cardiovascular Disease page.
2 Phase 3
Head-to-head evidence: rosuvastatin/ezetimibe vs vytorin